A new treatment to quickly remove synthetic opioids from the body
Official title: A Therapeutic Agent to Lower the Level of Synthetic Opioids in the Body
Funded at Clear Scientific, LLC · NIH-10912013 · Data updated 2026-11-12
This study is testing a new treatment called CS-1103 that helps quickly remove dangerous synthetic opioids like fentanyl from the body, aiming to provide a single dose that can restore normal breathing and keep people safe after an overdose.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clear Scientific, LLC NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $3,051,790 |
| NIH project number | 5UG3DA059286-02 |
| Project ID | NIH-10912013 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of opioid overdose, including those with opioid use disorder or those who have been prescribed synthetic opioids.
✕Less likely to help
Patients who are not using synthetic opioids or who do not have a history of opioid use disorder may not benefit from this research.
What this research studies
This research focuses on developing a therapeutic agent, CS-1103, that can rapidly deactivate and eliminate synthetic opioids like fentanyl from the body. Unlike naloxone, which only temporarily blocks opioid receptors, CS-1103 binds to fentanyl in the bloodstream and enhances its clearance through urine, effectively reversing its life-threatening effects. The goal is to provide a single-dose treatment that restores normal breathing and prevents the risk of renarcotization, which can occur after overdose. The research has shown promising results in animal models, demonstrating quick recovery from opioid effects.
Why it matters
Potential benefit: If successful, this research could provide a life-saving treatment for individuals experiencing opioid overdoses, significantly reducing mortality rates.
How similar studies have gone: While naloxone has been widely used, this approach with CS-1103 is novel and aims to address limitations of existing treatments, making it a potentially groundbreaking advancement.
Where this research is happening
-
Clear Scientific, LLC
Cambridge, United States Active
Researchers
- Principal investigator: Li, Xinhua — Clear Scientific, LLC
- Study coordinator: Li, Xinhua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.